The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder.

Transl Psychiatry · 2019 · PMC6722075 · PMID 31481683

Europe PMC DOI

hedged sentences

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

a nonsignificant trendp < 0.10so close (0.05 < p ≤ 0.1)

Improvements in depressive symptoms following seltorexant (but not placebo and diphenhydramine) however, showed a nonsignificant trend toward a positive correlation with improvement in SE ( p < 0.10); neither changes in WASO nor in duration of stage 2 sleep correlated with improvements in depressive symptoms in any treatment group.

also in 5,406 other papers

showed a trendno p-value reported

While seltorexant administration was not associated with significant changes in PSG parameters, it showed a trend towards improving patients’ self-reported sleep experience.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.